Metabolomic analyses for atherosclerosis, diabetes, and obesity

被引：50
作者：
Du F. [1 ,2 ,3 ]
Virtue A. [1 ,2 ,3 ]
Wang H. [1 ,2 ,3 ]
Yang X.-F. [1 ,2 ,3 ]
机构：
[1] Department of Pharmacology, Temple University School of Medicine, Philadelphia
[2] Cardiovascular Research Center and Department of Pharmacology, Temple University School of Medicine, 3500 North Broad Street, MERB 1059, Philadelphia
[3] Thrombosis Research Center, Temple University School of Medicine, Philadelphia
来源：
Biomarker Research | / 1卷 / 1期
基金：
美国国家卫生研究院;
关键词：
Atherosclerosis; Diabetes; Metabolites; Metabolomics analysis; Obesity;
D O I：
10.1186/2050-7771-1-17
中图分类号：
学科分类号：
摘要：
Insulin resistance associated with type 2 diabetes mellitus (T2DM), obesity, and atherosclerosis is a global health problem. A portfolio of abnormalities of metabolic and vascular homeostasis accompanies T2DM and obesity, which are believed to conspire to lead to accelerated atherosclerosis and premature death. The complexity of metabolic changes in the diseases presents challenges for a full understanding of the molecular pathways contributing to the development of these diseases. The recent advent of new technologies in this area termed " Metabolomics" may aid in comprehensive metabolic analysis of these diseases. Therefore, metabolomics has been extensively applied to the metabolites of T2DM, obesity, and atherosclerosis not only for the assessment of disease development and prognosis, but also for the biomarker discovery of disease diagnosis. Herein, we summarize the recent applications of metabolomics technology and the generated datasets in the metabolic profiling of these diseases, in particular, the applications of these technologies to these diseases at the cellular, animal models, and human disease levels. In addition, we also extensively discuss the mechanisms linking the metabolic profiling in insulin resistance, T2DM, obesity, and atherosclerosis, with a particular emphasis on potential roles of increased production of reactive oxygen species (ROS) and mitochondria dysfunctions. © 2013 Du et al.; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 84 条
[51]  
Bugiardini, R., Manfrini, O., Pizzi, C., Fontana, F., Morgagni, G., Endothelial function predicts future development of coronary artery disease: a study of women with chest pain and normal coronary angiograms (2004) Circulation, 109, pp. 2518-2523. , 10.1161/01.CIR.0000128208.22378.E3, 15136498
[52]  
Williams, I.L., Chowienczyk, P.J., Wheatcroft, S.B., Patel, A.G., Sherwood, R.A., Momin, A., Shah, A.M., Kearney, M.T., Endothelial function and weight loss in obese humans (2005) Obes Surg, 15, pp. 1055-1060. , 10.1381/0960892054621134, 16105407
[53]  
Melikian, N., Kearney, M.T., Thomas, M.R., De Bruyne, B., Shah, A.M., MacCarthy, P.A., A simple thermodilution technique to assess coronary endothelium-dependent microvascular function in humans: validation and comparison with coronary flow reserve (2007) Eur Heart J, 28, pp. 2188-2194. , 10.1093/eurheartj/ehm269, 17644509
[54]  
Momin, A., Melikian, N., Wheatcroft, S.B., Grieve, D., John, L.C., El Gamel, A., Marrinan, M.T., Sherwood, R., The association between saphenous vein endothelial function, systemic inflammation, and statin therapy in patients undergoing coronary artery bypass surgery (2007) J Thorac Cardiovasc Surg, 134, pp. 335-341. , 10.1016/j.jtcvs.2006.12.064, 17662770
[55]  
Steinberg, H.O., Chaker, H., Leaming, R., Johnson, A., Brechtel, G., Baron, A.D., Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance (1996) J Clin Invest, 97, pp. 2601-2610. , 10.1172/JCI118709, 507347, 8647954
[56]  
Laine, H., Yki-Jarvinen, H., Kirvela, O., Tolvanen, T., Raitakari, M., Solin, O., Haaparanta, M., Nuutila, P., Insulin resistance of glucose uptake in skeletal muscle cannot be ameliorated by enhancing endothelium-dependent blood flow in obesity (1998) J Clin Invest, 101, pp. 1156-1162. , 10.1172/JCI1065, 508668, 9486987
[57]  
Tack, C.J., Ong, M.K., Lutterman, J.A., Smits, P., Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone (1998) Diabetologia, 41, pp. 569-576. , 10.1007/s001250050948, 9628275
[58]  
Westerbacka, J., Vehkavaara, S., Bergholm, R., Wilkinson, I., Cockcroft, J., Yki-Jarvinen, H., Marked resistance of the ability of insulin to decrease arterial stiffness characterizes human obesity (1999) Diabetes, 48, pp. 821-827. , 10.2337/diabetes.48.4.821, 10102699
[59]  
Williams, I.L., Wheatcroft, S.B., Shah, A.M., Kearney, M.T., Obesity, atherosclerosis and the vascular endothelium: mechanisms of reduced nitric oxide bioavailability in obese humans (2002) Int J Obes Relat Metab Disord, 26, pp. 754-764
[60]  
Noronha, B.T., Li, J.M., Wheatcroft, S.B., Shah, A.M., Kearney, M.T., Inducible nitric oxide synthase has divergent effects on vascular and metabolic function in obesity (2005) Diabetes, 54, pp. 1082-1089. , 10.2337/diabetes.54.4.1082, 15793247
123456789